FDMT SEC申報文件 - 4D Molecular Therapeutics, Inc.-年度報告，委任書，招股章程

基本數據

CIK

1650648

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to 4D Molecular Therapeutics, Inc.

SEC Filings (Chronological Order)

本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。

May 7, 2026	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2026 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Commi
May 7, 2026	EX-99.1	4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones Exhibit 99.1 4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones • 4D-150 4FRONT-1 wet AMD Phase 3 randomization complete (N=523); topline data expected in H1 2027 • 4FRONT - 2 enrollment completion expected in H2 2026; topline data expected in H2 2027 • 4D-150 PRISM wet AMD Phase 2b 2-year data expected at a scientific conference in Q3 2026,
May 7, 2026	S-3	As filed with the Securities and Exchange Commission on May 7, 2026 S-3 Table of Contents As filed with the Securities and Exchange Commission on May 7, 2026 Registration No.
May 7, 2026	EX-4.4	4D MOLECULAR THERAPEUTICS, INC. Dated as of ___________, 20___ as Trustee EX-4.4 Exhibit 4.4 4D MOLECULAR THERAPEUTICS, INC. INDENTURE Dated as of , 20 [ ] as Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 6 Section 2.1. Issuable in Seri
May 7, 2026	EX-10.1	4D Molecular Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Program Exhibit 10.1 4D Molecular Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Program This 4D Molecular Therapeutics, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2020 Incentive Award Plan (the “Plan”) and has been amended and restated effective as of March 25, 2026 (the “Effective Date”). Capitalized t
May 7, 2026	EX-FILING FEES	Security Type Calculation of Filing Fee Tables S-3 4D Molecular Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry For
May 7, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecul
April 28, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D
April 28, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy S
April 28, 2026	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) շ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ն TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecular Th
March 30, 2026	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2026 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Com
March 18, 2026	EX-10.24	COLLABORATION AND LICENSE AGREEMENT Certain confidential information contained in this document, marked by brackets and asterisk, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because the Company treats such information as private or confidential and the omitted information is not material.
March 18, 2026	EX-10.22	4D MOLECULAR THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT 4D MOLECULAR THERAPEUTICS, INC. EXECUTIVE Exhibit 10.22 4D MOLECULAR THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Kristian F. Humer (“Executive”) and 4D Molecular Therapeutics, Inc. (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”). Background
March 18, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecular Th
March 18, 2026	EX-10.21	November 3, 2025 Exhibit 10.21 November 3, 2025 Kristian Humer Dear Kristian: We are pleased to make you the following offer of employment. We believe you will play an important and meaningful role in our mission of developing genetic medicines for large market diseases. Position. Your title will be Chief Financial Officer, reporting to David Kirn, with a start date of November 17, 2025 (the date you actually comm
March 18, 2026	EX-10.23	“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER S Exhibit 10.23 TRANSITION AGREEMENT This Transition Agreement (the “Agreement”) by and between Fred Kamal, Ph.D. (“Executive”) and 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company” and, together with Executive, the “Parties”) is made effective as of the eighth day following the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts: A.
March 18, 2026	S-8	As filed with the Securities and Exchange Commission on March 18, 2026 S-8 As filed with the Securities and Exchange Commission on March 18, 2026 Registration No.
March 18, 2026	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2026 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Com
March 18, 2026	EX-4.1	Authorized Capital Stock Common Stock Preferred Stock Warrants Anti-Takeover Effects of Provisions of Our Amended and Restated Certificate of Incorporation, Our Amended and Restated Bylaws and Delaware Law Limitations of Liability and Indemnification Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2025, 4D Molecular Therapeutics, Inc. had one class of common stock registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following summary describes our capital stock and the material provisions of our
March 18, 2026	EX-99.1	4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones Exhibit 99.1 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones • Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data expected in H1 2027 • PRISM wet AMD Phase 2b 2-year data expected in mid-2026 and
March 18, 2026	EX-FILING FEES	Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 4D Molecular Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, $0.0001 par value per share Other 2,880,394 $ 8.36 $ 24,080,093.84 0.0001381 $ 3,325.47
March 18, 2026	EX-10.16	“Number of Shares. Subject to adjustment under Article IX and the terms of this Article V, Awards may be made under the Plan covering up to 1,500,000 Shares. Shares issued or delivered under the Plan may consist of authorized but unissued Shares, Sha Exhibit 10.16 AMENDMENT TO 4D MOLECULAR THERAPEUTICS, INC. 2025 EMPLOYMENT INDUCEMENT AWARD PLAN This amendment (“Amendment”) to the 2025 Employment Inducement Award Plan (the “Inducement Plan”) of 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”) is made pursuant to Section 11.4 of the Plan, effective as of January 23, 2026. WITNESSETH THAT: WHEREAS, the Company presently ma
January 26, 2026	EX-4.1	4D MOLECULAR THERAPEUTICS, INC. [FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK Exhibit 4.1 4D MOLECULAR THERAPEUTICS, INC. [FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. CS – [ ] Original Issue Date: January 22, 2026 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ]
January 26, 2026	8-K	FORM 8-K Item 3.02 Unregistered Sales of Equity Securities. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2026 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
January 7, 2026	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2025 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (
December 10, 2025	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2025 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (
November 17, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2025 4D Molecular Th UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2025 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (
November 10, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Mol
November 10, 2025	EX-99.1	4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones Exhibit 99.1 4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones • Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to receive $85 million in upfront cash and expects to receive at least $50 million from cost sharing • Announced positive long-term safety
November 10, 2025	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (
November 10, 2025	EX-10.1	Exhibit 10.1 US-DOCS\146996649.2 DocuSign Envelope ID: E0E94006-E660-4306-A3D8-B2CD8319BF9F Exhibit 10.1 May 24, 2024 Ashoo Gupta ********@gmail.com Dear Ashoo: We are pleased to make you the following offer of employment. We believe you will play an important and meaningful role in our mission of curing people of hereditary diseases. Position. Your title will be Vice President, Finance & Controller, reporting
November 10, 2025	EX-10.2	Exhibit 10.2 4D MOLECULAR THERAPEUTICS, INC. Exhibit 10.2 4D MOLECULAR THERAPEUTICS, INC. THIS CONSULTING AGREEMENT (the “Agreement”) by and between 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), and Uneek Mehra (“Consultant”) is effective as of July 15, 2025 (the “Effective Date”). The Company and the Consultant may be referred to herein individually as “Party” or collectively, as “Parties.” Recitals WHEREAS, Consu
November 7, 2025	EX-1.1	4D MOLECULAR THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.0001 PER SHARE PRE-FUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 Execution Version 4D MOLECULAR THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.0001 PER SHARE PRE-FUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK UNDERWRITING AGREEMENT November 6, 2025 Leerink Partners LLC Evercore Group L.L.C. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Leerink Partners LLC 1301 Avenue of the Americas,
November 7, 2025	EX-4.1	4D MOLECULAR THERAPEUTICS, INC. [FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. CS - [ ] Original Issue Date: November [ ], 2025 EX-4.1 Exhibit 4.1 4D MOLECULAR THERAPEUTICS, INC. [FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. CS - [ ] Original Issue Date: November [ ], 2025 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowle
November 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 4D Molecular The UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
November 6, 2025	424B5	8,385,809 Shares of Common Stock Pre-Funded Warrants to Purchase 1,128,949 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-273845 PROSPECTUS SUPPLEMENT (To Prospectus dated August 15, 2023) 8,385,809 Shares of Common Stock Pre-Funded Warrants to Purchase 1,128,949 Shares of Common Stock 4D Molecular Therapeutics, Inc. is offering 8,385,809 shares of its common stock, par value $0.0001 per share, and, in lieu of shares of common stock to cert
November 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 4D Molecular The UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
October 31, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2025 4D Molecular The UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2025 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
October 2, 2025	EX-3.1	ARTICLE I - CORPORATE OFFICES ARTICLE II - MEETINGS OF STOCKHOLDERS ARTICLE III - DIRECTORS ARTICLE IV - COMMITTEES ARTICLE V - OFFICERS ARTICLE VI - RECORDS AND REPORTS ARTICLE VII - GENERAL MATTERS ARTICLE VIII - NOTICE BY ELECTRONIC TRANSMISSION A EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS OF 4D MOLECULAR THERAPEUTICS, Inc. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 2 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCE
October 2, 2025	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2025 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation)
September 23, 2025	144	144 144 0001920738 XXXXXXXX LIVE 0001650648 4D MOLECULAR THERAPEUTICS, INC. 001-39782 5858 Horton Street, #455 Emeryville CA 94608 5105052680 SCOTT BIZILY Officer COMMON Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 7312 54108.80 46702467 09/23/2025 NASDAQ Common 09/23/2025 Exercise of Stock Options Issuer N 4905 09/23/2025 Cash Common 11/14/
August 11, 2025	EX-99.1	4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones Exhibit 99.1 4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones • 4D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedule • Presented positive 60-week results from 4D-150 SPECTRA clinical trial in DME • Streamlined organization
August 11, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecula
August 11, 2025	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Com
July 2, 2025	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Comm
June 20, 2025	8-K	FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Comm
May 8, 2025	S-8	Power of Attorney (included in the signature page to this registration statement). S-8 As filed with the Securities and Exchange Commission on May 8, 2025 Registration No.
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecul
May 8, 2025	EX-99.1	4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones Exhibit 99.1 4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones • Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to date • Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-1 and 4FRONT-2 expected i
May 8, 2025	EX-FILING FEES	Calculation of Filing Fee Table. Calculation of Filing Fee Tables S-8 4D Molecular Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, $0.0001 par value per share Other 307,939 $ 2.68 $ 825,276.52 0.0001531 $ 126.35 Total
May 8, 2025	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Commis
April 29, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy S
April 29, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D
April 29, 2025	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecular Th
February 28, 2025	EX-10.19	2025 Employment Inducement Award Plan. Exhibit 10.19 4D Molecular Therapeutics, Inc. 2025 EMPLOYMENT INDUCEMENT AWARD PLAN ARTICLE I. Purpose The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate employees who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. ARTICLE II. Definitions As used in the Plan, the following words and
February 28, 2025	POSASR	As filed with the Securities and Exchange Commission on February 28, 2025 Table of Contents As filed with the Securities and Exchange Commission on February 28, 2025 Registration No.
February 28, 2025	S-8	As filed with the Securities and Exchange Commission on February 28, 2025 S-8 As filed with the Securities and Exchange Commission on February 28, 2025 Registration No.
February 28, 2025	EX-4.1	Description of Securities of the Registrant. Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, 4D Molecular Therapeutics, Inc. had one class of common stock registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following summary describes our capital stock and the material provisions of our
February 28, 2025	POS AM	Powers of Attorney (incorporated by reference to the signature page hereto). Table of Contents As filed with the Securities and Exchange Commission on February 28, 2025 Registration No.
February 28, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Regist
February 28, 2025	EX-10.20	Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2025 Employment Inducement Award Plan. Exhibit 10.20 4D MOLECULAR THERAPEUTICS, INC. 2025 EMPLOYMENT INDUCEMENT AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), pursuant to its 2025 Employment Inducement Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”), an award of restricted stock units (“Restr
February 28, 2025	EX-19.1	Insider Trading Compliance Policy, dated as of November 4, 2024 Certain confidential information contained in this document, marked by brackets and asterisks, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because the Company treats such information as private or confidential and the omitted information is not material.
February 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
February 28, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecular Th
February 28, 2025	EX-10.21	Form of Stock Option Grant Notice and Stock Option Agreement under the 2025 Employment Inducement Award Plan. Exhibit 10.21 4D MOLECULAR THERAPEUTICS, INC. 2025 EMPLOYMENT INDUCEMENT AWARD PLAN STOCK OPTION GRANT NOTICE 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), pursuant to its 2025 Employment Inducement Award Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an option to purchase the number of shares of the Comp
February 28, 2025	EX-99.1	4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones Exhibit 99.1 4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones • Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and continued favorable tolerability • Announced positive interim 32-week data
February 28, 2025	EX-FILING FEES	Calculation of Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common s
February 14, 2025	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ex-99-02142025110212.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United State
February 14, 2025	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ex-99-02142025110233.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of 4D Molecular Therapeutics, Inc. and further agree th
February 14, 2025	SCHEDULE 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / BIOTECHNOLOGY VALUE FUND L P Passive Investment SCHEDULE 13G/A 0000921895-21-001775 0000918923 XXXXXXXX LIVE 4 Common Stock, par value $0.
February 10, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 08, 2025 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
February 10, 2025	SCHEDULE 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / GOLDMAN SACHS GROUP INC Passive Investment SCHEDULE 13G/A 0000769993-24-000356 0000886982 XXXXXXXX LIVE 1 Common Stock, par value $0.
February 10, 2025	EX-99	EX-99 EX-99 2 POA13G-2468332120250128.txt EXHIBIT 99 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS that THE GOLDMAN SACHS GROUP, INC. (the "Company") does hereby make, constitute and appoint Papa Lette, Akash Keshari, Regina Chan, Andrzej Szyszka, Ameen Soetan, Rahail Patel, Santosh Vinayagamoorthy, Sadhiya Raffique, Matthew Pomfret, Abhishek Vishwanathan, Mariana Audeves, Veronica Mupazviriwo, E
January 10, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Co
January 10, 2025	EX-99.1	Legal Disclaimer This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Presentation, including statements regarding our cli Intravitreal 4D-150 DME Clinical Trial: Part 1 Interim 32-week Results January 10, 2025 EXHIBIT 99.
December 11, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 06, 2024 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
December 11, 2024	EX-4.1	Form of Pre-Funded Warrant issued in conjunction with December 2024 exchange. Exhibit 4.1 4D MOLECULAR THERAPEUTICS, INC. [FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK Number of Shares: 535,000 (subject to adjustment) Warrant No. CS - 8 Original Issue Date: December [ ], 2024 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
December 6, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / BlackRock, Inc. Passive Investment SC 13G/A 1 us35104e1001120624.txt us35104e1001120624.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) 4D Molecular Therapeutics Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 35104E100 - (CUSIP Number) November 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the app
November 15, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2428635d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* 4D MOLECULAR THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 35104E100 (CUSIP Number) November 13, 2024 (Date of Event Which Requires Filing of this
November 15, 2024	EX-99.1	Exhibit 1: Joint Filing Agreement EX-99.1 2 tm2428635d1ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 15, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio
November 14, 2024	EX-99.1	Exhibit 1: Joint Filing Agreement EX-99.1 2 tm2427451d5ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio
November 14, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / VIKING GLOBAL INVESTORS LP Passive Investment SC 13G/A 1 sayw2411142413ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 5) 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Tit
November 14, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2427451d5sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* 4D MOLECULAR THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 35104E100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this
November 14, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-fdmt093024a4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* 4D MOLECULAR THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 35104E100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this State
November 14, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / JANUS HENDERSON GROUP PLC - JANUS AMENDMENT Passive Investment SC 13G/A 1 4D093024.txt JANUS AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 3* Name of Issuer: 4D Molecular Therapeutics, Inc. Title of Class of Securities: Common Stock CUSIP Number: 35104E100 Date of Event Which Requires Filing of this Statement: 9/30/2024 Check the appropriate box to design
November 13, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
November 13, 2024	EX-99.1	4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones Exhibit 99.1 4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones • Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and intraocular inflammation (IOI) profile numerically similar t
November 13, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 3 TO SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga307422fdmt11142024.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, par
November 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Mol
November 13, 2024	EX-4.4	Form of Pre-Funded Warrant issued in conjunction with November 2024 exchange. Exhibit 4.4 4D MOLECULAR THERAPEUTICS, INC. [FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. CS - [ ] Original Issue Date: October [ ], 2024 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [
November 12, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / VANGUARD GROUP INC Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) 4D Molecular Therapeutics Inc (Title of Class of Securities) Common Stock (CUSIP Numb
November 8, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / BlackRock, Inc. Passive Investment SC 13G/A 1 us35104e1001110824.txt us35104e1001110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) 4D Molecular Therapeutics Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 35104E100 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the ap
November 6, 2024	SC 13G	FDMT / 4D Molecular Therapeutics, Inc. / GOLDMAN SACHS GROUP INC Passive Investment SC 13G 1 4DMolecular.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 4D MOLECULAR THERAPEUTICS, INC. - (Name of Issuer) Common Stock, par value $0.0001 per share - (Title of Class of Securities) 35104E100 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement)
November 4, 2024	SC 13G	FDMT / 4D Molecular Therapeutics, Inc. / VANGUARD GROUP INC Passive Investment SC 13G 1 UnitedStates13G4DMolecula.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) 4D Molecular Therapeutics Inc (Title of Class o
October 21, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / BlackRock, Inc. Passive Investment SC 13G/A 1 us35104e1001102124.txt us35104e1001102124.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) 4D Molecular Therapeutics Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 35104E100 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the ap
September 18, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation)
August 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2024 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Com
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecula
August 8, 2024	EX-99.1	4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights Exhibit 99.1 4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights • Announced positive interim results from the Population Extension cohort of the Phase 2 PRISM clinical trial for 4D-150 in a broad wet age-related macular degeneration (wet AMD) population, which includes patients representative of the planned Phase 3 study population, affirming favorable safety profile and
July 23, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 4D Molecular Therap UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Comm
July 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2024 4D MOLECULAR THERAP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2024 4D MOLECULAR THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (Comm
June 24, 2024	144	144 144 0001834021 XXXXXXXX LIVE 0001650648 4D Molecular Therapeutics, Inc. 001-39782 5858 Horton Street Suite 455 Emeryville CA 94608 1-510-505-2680 David Kirn Officer Class A Common Goldman Sachs & Co. LLC 200 West Street New York NY 10282 12930 300622.5 51703412 06/24/2024 NASD Class A Common 02/10/2022 Acquired as compensation - Stock Options Issuer N 4625 06/24/2024 Compensation - Cashless exerci
June 7, 2024	EX-1.1	Sales Agreement, dated June 7, 2024, by and between the Company and Leerink Partners LLC Exhibit 1.1 SALES AGREEMENT June 7, 2024 Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Leerink Partners LLC, as sales agent and/or principal (the “Agent”), shar
June 7, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Commi
June 7, 2024	EX-FILING FEES	CALCULATION OF FILING FEE TABLE (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Propos Exhibit 107.1 CALCULATION OF FILING FEE TABLE 424(b)(5) (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Sec
June 7, 2024	424B5	Up to $250,000,000 Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-276872 PROSPECTUS SUPPLEMENT (To Prospectus dated February 5, 2024) Up to $250,000,000 Common Stock We have entered into a sales agreement (sales agreement) with Leerink Partners LLC (Leerink Partners) dated June 7, 2024, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospect
May 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 4D Molecular Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 4D Molecular Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Commi
May 9, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Commis
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecul
May 9, 2024	EX-99.1	4DMT Reports First Quarter 2024 Financial Results and Operational Highlights Exhibit 99.1 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights • Announced positive interim data from PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden enabling advancement into Phase 3 expected by Q1 2025 • Interim 24-week landmark analysis from PRISM Phase 2 Population Extension cohort evalu
April 10, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy S
April 10, 2024	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecular Th
April 10, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D
February 29, 2024	EX-99.1	4DMT Reports Full Year 2023 Financial Results and Operational Highlights Exhibit 99.1 4DMT Reports Full Year 2023 Financial Results and Operational Highlights • Presented positive interim data from randomized Dose Expansion cohort of the Phase 2 PRISM study evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden, enabling advancement into Phase 3 pivotal development, with initiation expected in Q1 2025 • Positive interim clinical da
February 29, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecular Th
February 29, 2024	EX-10.15	Change in Control and Severance Agreement, dated August 29, 2023, by and between Uneek Mehra and the Registrant Exhibit 10.15 4D MOLECULAR THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between (“Executive”) and 4D Molecular Therapeutics, Inc. (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”). Background A. The Board of D
February 29, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
February 29, 2024	EX-97	Registrant’s Policy for Recovery of Erroneously Awarded Compensation Exhibit 97 4D MOLECULAR THERAPEUTICS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION 4D Molecular Therapeutics, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11 of this Pol
February 29, 2024	EX-10.17	Amended and Restated Change in Control and Severance Agreement, dated June 23, 2023 by and between Robert Kim and the Registrant Exhibit 10.17 4D MOLECULAR THERAPEUTICS, INC. AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Robert Young Kim (“Executive”) and 4D Molecular Therapeutics, Inc. (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto
February 29, 2024	EX-FILING FEES	Calculation of Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common st
February 29, 2024	EX-10.14	Offer Letter, dated September 4, 2023, between Uneek Mehra and the Registrant Exhibit 10.14 September 4, 2023 Uneek Mehra 714 Jacaranda Circle Hillsborough, CA 94010 Dear Uneek: We are pleased to make you the following offer of employment. We believe you will play an important and meaningful role in our mission of developing transformative genetic medicines for our patients. Position and Location of Role. Your title will be Chief Financial and Business Officer, reporting to
February 29, 2024	EX-10.16	Change in Control and Severance Agreement, dated September 22, 2021, by and between Scott Bizily and the Registrant Exhibit 10.16 4D MOLECULAR THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Scott Bizily (“Executive”) and 4D Molecular Therapeutics, Inc. (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”). Background A. T
February 29, 2024	S-8	As filed with the Securities and Exchange Commission on February 29, 2024 As filed with the Securities and Exchange Commission on February 29, 2024 Registration No.
February 14, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / Kirn David - SC 13G/A Passive Investment SC 13G/A 1 d780455dsc13ga.htm SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stoc
February 14, 2024	EX-99.1	Exhibit 1: Joint Filing Agreement EX-99.1 2 tm246065d1ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission
February 14, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga207422fdmt02142024.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, par
February 14, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / Venrock Healthcare Capital Partners III, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246235d11sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 35104E100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this
February 14, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246065d113ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* 4D MOLECULAR THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 35104E100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Sta
February 13, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / JANUS HENDERSON GROUP PLC - JHG PLC OWNS >5% Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 2* Name of Issuer: 4D Molecular Therapeutics, Inc. Title of Class of Securities: Common Stock CUSIP Number: 35104E100 Date of Event Which Requires Filing of this Statement: 12/31/2023 Check the appropriate box to designate the rule pursuant to which this Sch
February 9, 2024	EX-4.1	Form of Pre-Funded Warrant issued in conjunction with February 2024 offering. Exhibit 4.1 4D MOLECULAR THERAPEUTICS, INC. [FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. CS - [ ] Original Issue Date: February [ ], 2024 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [
February 9, 2024	EX-1.1	Underwriting Agreement, dated as of February 6, 2024, among 4D Molecular Therapeutics, Inc. and Goldman Sachs & Co. LLC, BofA Securities, Inc., Jefferies LLC and Barclays Capital Inc. Exhibit 1.1 4D Molecular Therapeutics, Inc. Common Stock, par value $0.0001 per share Pre-Funded Warrants to Purchase Shares of Common Stock Underwriting Agreement February 6, 2024 Goldman Sachs & Co. LLC BofA Securities, Inc. Jefferies LLC Barclays Capital Inc. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West St
February 9, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 4D MOLECULAR THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (C
February 8, 2024	424B5	6,586,015 Shares of Common Stock Pre-funded Warrants to Purchase 3,583,476 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-276872 PROSPECTUS SUPPLEMENT (To Prospectus dated February 5, 2024) 6,586,015 Shares of Common Stock Pre-funded Warrants to Purchase 3,583,476 Shares of Common Stock We are offering up to 6,586,015 shares of our common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 3,583,476 shar
February 8, 2024	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) 4D Molecular Therapeutics, Inc.
February 7, 2024	FWP	Common Stock Pre-funded Warrants to Purchase Shares of Common Stock Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated February 6, 2024 Relating to Preliminary Prospectus Supplement Dated February 5, 2024 Registration Statement No.
February 5, 2024	S-3ASR	As filed with the Securities and Exchange Commission on February 5, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 5, 2024 Registration No.
February 5, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 CALCULATION OF FILING FEE TABLE S-3ASR (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Re
February 5, 2024	424B5	Subject to Completion, Dated February 5, 2024 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-276872 The information contained in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offe
February 5, 2024	EX-4.3	Form of Indenture Exhibit 4.3 4D MOLECULAR THERAPEUTICS, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 6 Section 2.1. Issuable in Series 6 Section
January 25, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / BlackRock Inc. Passive Investment us35104e1001012524.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) 4D Molecular Therapeutics Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 35104E100 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
January 8, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment SC 13G/A 1 ef20018319sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 4) 4D Molecular Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per s
January 8, 2024	SC 13G/A	FDMT / 4D Molecular Therapeutics, Inc. / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment SC 13G/A 1 ef20018316sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 3) 4D Molecular Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per s
January 5, 2024	144	144 144 0001834021 XXXXXXXX LIVE 0001650648 4D Molecular Therapeutics, Inc. 001-39782 5858 Horton Street Suite 455 Emeryville CA 94608 1-510-505-2680 David Kirn Officer Class A Common Goldman Sachs & Co. LLC 200 West Street New York NY 10282 28237 553162.83 42753607 01/05/2024 NASD Class A Common 12/15/2020 Founder's Shares Issuer N 28237 12/15/2020 None N David Kirn 5858 Horton Street Suite 455 Emery
January 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2024 4D MOLECULAR THER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2024 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (Co
November 22, 2023	EX-3.1	Amended and Restated Bylaws, as currently in effect. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF 4D MOLECULAR THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCE
November 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 4D MOLECULAR TH UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Mol
November 9, 2023	EX-99.1	4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights Exhibit 99.1 4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights • Rapidly advanced 4D-150 development for wet age-related macular degeneration (wet AMD): completed enrollment of PRISM Phase 2 Dose Expansion nearly two quarters earlier than expected and enrolled first patient in Population Extension cohort • Interim data update from 4D-150 PRISM Phase 2 Dose Expansion (n=5
November 9, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
November 9, 2023	EX-10.1	License Agreement between the Registrant and Astellas Gene Therapies, Inc., dated as of July 5, 2023 Certain confidential information contained in this document, marked by brackets and asterisk, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because the Company treats such information as private or confidential and the omitted information is not material.
September 13, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation)
August 11, 2023	CORRESP	4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 August 11, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Jason Drory Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-273845) To the addre
August 11, 2023	LETTER	LETTER United States securities and exchange commission logo August 11, 2023 David Kirn, M.
August 9, 2023	EX-4.5	Form of Indenture EX-4.5 Exhibit 4.5 4D MOLECULAR THERAPEUTICS, INC. INDENTURE Dated as of , 20 [ ] as Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Sec
August 9, 2023	EX-99.1	4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights Exhibit 99.1 4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights • Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for patients with wet age-related macular degeneration (wet AMD) • Completed target enrollment of 50 patients in the randomized Phase 2 Dose Expansion stage of the PRISM clinical trial in July, near
August 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecula
August 9, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2023 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Com
August 9, 2023	EX-FILING FEES	Fee Table Exhibit EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate(4
August 9, 2023	S-3	As filed with the Securities and Exchange Commission on August 9, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on August 9, 2023 Registration No.
July 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2023 4D MOLECULAR THERAPE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2023 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (Commi
June 5, 2023	SC 13G	FDMT / 4D Molecular Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 4D MOLECULAR THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 35104E100 (CUSIP Number) May 25, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
May 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 4D MOLECULAR THERAPE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (Commi
May 15, 2023	SC 13G	FDMT / 4D Molecular Therapeutics Inc / Venrock Healthcare Capital Partners III, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 35104E100 (CUSIP Number) May 5, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t
May 11, 2023	EX-99	4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights Exhibit 99.1 4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights • Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration (wet AMD) at the 2023 ARVO Annual Meeting • On track for completion of enrollment of the Phase 2 Dose Expansion Stage of the PRISM clinical trial in Q3 2023 •
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecul
May 11, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Commis
May 9, 2023	EX-1.1	Underwriting Agreement, dated as of May 4, 2023, among 4D Molecular Therapeutics, Inc. and Goldman Sachs & Co. LLC, BofA Securities, Inc. and Evercore Group, L.L.C. Exhibit 1.1 4D Molecular Therapeutics, Inc. Common Stock, par value $0.0001 per share Underwriting Agreement May 4, 2023 Goldman Sachs & Co. LLC BofA Securities, Inc. Evercore Group L.L.C. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o BofA Securities, Inc. One Bryant Park Ne
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 4D MOLECULAR THERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 4D MOLECULAR THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (Commis
May 8, 2023	424B5	Prospectus Supplement to Prospectus Dated April 15, 2022 7,500,000 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263925 Prospectus Supplement to Prospectus Dated April 15, 2022 7,500,000 Shares Common Stock 4D Molecular Therapeutics, Inc. is offering 7,500,000 shares of its common stock, par value $0.0001 per share. Our common stock is listed on the Nasdaq Global Select Market under the symbol “FDMT.” On May 4, 2023, the last repor
May 4, 2023	424B5	Subject to Completion, Dated May 4, 2023 Prospectus Supplement to Prospectus Dated April 15, 2022 Common Stock 424B5 1 d557482d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263925 The information contained in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompa
May 4, 2023	S-8 POS	As filed with the Securities and Exchange Commission on May 3, 2023 S-8 POS As filed with the Securities and Exchange Commission on May 3, 2023 Registration No.
April 12, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro
April 12, 2023	DEF 14A	Schedule 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 15, 2023	EX-FILING FEES	Calculation of Filing Fee Table EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee E
March 15, 2023	S-8	As filed with the Securities and Exchange Commission on March 15, 2023 S-8 As filed with the Securities and Exchange Commission on March 15, 2023 Registration No.
March 15, 2023	EX-4	Description of Securities of the Registrant. Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, 4D Molecular Therapeutics, Inc. had one class of common stock registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following summary describes our capital stock and the material provisions of our
March 15, 2023	EX-99	4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights Exhibit 99.1 4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights • Provided updates on clinical pipeline, including 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for cystic fibrosis lung disease, and 4D-310 for Fabry disease cardiomyopathy • Demonstrated robust clinical gene delivery, tolerability and in
March 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Comm
March 15, 2023	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecular Th
February 14, 2023	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 9, 2023	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / JANUS HENDERSON GROUP PLC - JHI PLC OWNS <5% Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 1* Name of Issuer: 4D Molecular Therapeutics, Inc. Title of Class of Securities: Common Stock CUSIP Number: 35104E100 Date of Event Which Requires Filing of this Statement: 12/31/2022 Check the appropriate box to designate the rule pursuant to which this Sch
February 8, 2023	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / Kirn David - SC 13G/A Passive Investment SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of
February 3, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (C
January 31, 2023	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us35104e1001013123.txt us35104e1001013123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) 4D Molecular Therapeutics Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 35104E100 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the app
January 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 4D Molecular Ther UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 4D Molecular Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (Co
November 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2022 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
November 9, 2022	EX-99.1	4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results - Interim clinical trial data from 4DMT’s Phase 1/2 clinical trial of 4D-710 for the treatment of cystic fibrosis lung disease was presented at North American Cystic Fibrosis Conf Exhibit 99.1 4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results - Interim clinical trial data from 4DMT?s Phase 1/2 clinical trial of 4D-710 for the treatment of cystic fibrosis lung disease was presented at North American Cystic Fibrosis Conference on November 3, 2022 - Cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2025 E
November 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number: 001-39782 4D
September 27, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2022 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation)
September 1, 2022	CORRESP	4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 September 1, 2022 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Dillon Hagius Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-26701
August 30, 2022	LETTER	LETTER United States securities and exchange commission logo August 30, 2022 David Kirn, M.
August 23, 2022	EX-FILING FEES	Fee Table Exhibit Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Regist
August 23, 2022	S-3	As filed with the Securities and Exchange Commission on August 22, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 22, 2022 Registration No.
August 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Com
August 11, 2022	EX-99.1	4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update Exhibit 99.1 4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update ? Five clinical-stage product candidates on track for multiple clinical data updates in 2023 ? Cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2025 ? 4D-310 Phase 1/2 clinical trial eligible patient population expanded to incl
August 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number: 001-39782 4D Molec
June 21, 2022	EX-3.1	Amended and Restated Bylaws. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF 4D MOLECULAR THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCE
June 21, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (Comm
June 21, 2022	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 35104E 10 0 (CUS
May 27, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (Commi
May 12, 2022	EX-99.1	4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates Exhibit 99.1 4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates Emeryville, CA ? May 12, 2022 ? 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced first quarter 2022 financial results and provided corporate updates. ?We made s
May 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecul
May 12, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Commis
May 12, 2022	EX-10.1	Restated Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.1 4D Molecular Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Program This 4D Molecular Therapeutics, Inc. (the ?Company?) Non-Employee Director Compensation Program (this ?Program?) has been adopted under the Company?s 2019 Incentive Award Plan (the ?Plan?) and has been amended and restated effective as of March 21, 2022 (the ?Effective Date?). Capitalized t
April 15, 2022	EFFECT	EFFECT X0101 EFFECT 33 LIVE 2022-04-15 16:00:00 S-3 0001650648 4D Molecular Therapeutics Inc. 333-263925
April 13, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi
April 13, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
April 13, 2022	CORRESP	4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 April 13, 2022 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Alan Campbell Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-263925)
April 4, 2022	LETTER	LETTER United States securities and exchange commission logo April 4, 2022 David Kirn, M.
March 29, 2022	S-3	As filed with the Securities and Exchange Commission on March 28, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 28, 2022 Registration No.
March 29, 2022	EX-4.3	Form of Indenture Exhibit 4.3 4D MOLECULAR THERAPEUTICS, INC. INDENTURE Dated as of , 20 [ ], as Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2
March 29, 2022	EX-1.1	Open Market Sale AgreementSM by and between the Registrant and Jefferies LLC Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM March 28, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: 4D Molecular Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s
March 29, 2022	EX-FILING FEES	Fee Table Exhibit Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Regist
March 28, 2022	EX-99.1	4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights — Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125 and 4D-110 for inherited retinal dy Exhibit 99.1 4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights ? Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125 and 4D-110 for inherited retinal dystrophies, each demonstrating preliminary evidence of clinical activity ? Advanced two additional programs into clinical development: R10
March 28, 2022	EX-4.1	Exhibit 4.1 Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, 4D Molecular Therapeutics, Inc. had one class of common stock registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). The following summary describes our capital stock and the material provisions of our
March 28, 2022	S-8	As filed with the Securities and Exchange Commission on March 28, 2022 As filed with the Securities and Exchange Commission on March 28, 2022 Registration No.
March 28, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (Comm
March 28, 2022	EX-FILING FEES	Calculation of Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) 4D Molecular Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1?Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common st
March 28, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecular Th
February 22, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (
February 14, 2022	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / Kirn David - SC 13G/A Passive Investment SC 13G/A 1 d275210dsc13ga.htm SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* 4D Molecular Therapeutics Inc. (Name of Issuer) Common Stock
February 14, 2022	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / SCHAFFER DAVID - SC 13G/A Passive Investment United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* 4D Molecular Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of
February 14, 2022	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 2) 4D Molecular Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 35104
February 14, 2022	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 11, 2022	SC 13G	FDMT / 4D Molecular Therapeutics Inc / JANUS HENDERSON GROUP PLC - JANUS HENDERSON GROUP PLC OWNS >5% Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 0* Name of Issuer: 4D Molecular Therapeutics, Inc. Title of Class of Securities: Common Stock CUSIP Number: 35104E100 Date of Event Which Requires Filing of this Statement: 12/31/2021 Check the appropriate box to designate the rule pursuant to which this Sch
February 11, 2022	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / PFIZER INC - SC 13G/A 4D MOLECULAR Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) 1 4D Molecular Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 35104E100 (CUSIP Number) D
February 9, 2022	SC 13G/A	FDMT / 4D Molecular Therapeutics Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 1 4D MOLECULAR THERAPEUTICS INC COMMON STOCK Cusip #35104E100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #35104E100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 207,559 Item 6: 0 Item 7: 1,140,174 Item 8: 0 Item 9: 1,140,174 It
February 4, 2022	SC 13G	FDMT / 4D Molecular Therapeutics Inc / BlackRock Inc. Passive Investment us35104e1001020422.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) 4D Molecular Therapeutics Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 35104E100 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
January 11, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (C
January 11, 2022	EX-99.1	Legal Disclaimer This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Presentation, including statements regarding our cli Exhibit 99.1 Harnessing the Power of Directed Evolution for Targeted Gene Therapies Corporate Presentation \| January 2022 ? 2021 4D Molecular Therapeutics. All Rights Reserved. Legal Disclaimer This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Presentation, including s
November 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) (C
November 10, 2021	EX-10.4	Change in Control and Severance Agreement, dated September 22, 2021, by and between Fred Kamal and 4D Molecular Therapeutics, Inc. Exhibit 10.4 4D MOLECULAR THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the ?Agreement?) is made and entered into by and between Fariborz Kamal (?Executive?) and 4D Molecular Therapeutics, Inc. (the ?Company?), effective as of the latest date set forth by the signatures of the parties hereto below (the ?Effective Date?). Background A.
November 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Mol
November 10, 2021	EX-99.1	4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights Exhibit 99.1 4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights Emeryville, CA ? November 10, 2021 ? 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the third quarter of 2021, and provided operatio
November 4, 2021	SC 13G	FDMT / 4D Molecular Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
November 1, 2021	424B4	4,750,000 Shares Common Stock Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-260508 4,750,000 Shares Common Stock We are offering 4,750,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol ?FDMT.? On October 28, 2021, the last reported sale price of our common stock on the Nasdaq Global Select Market was $30.85 per share. We are an ?emerging gro
October 26, 2021	CORRESP	4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 October 26, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Michael Davis Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-1 (Registration No. 333-260508) Ladies an
October 26, 2021	EX-1.1	Form of Underwriting Agreement. Exhibit 1.1 4D Molecular Therapeutics, Inc. Common Stock, par value $0.0001 per share Underwriting Agreement October [?], 2021 Goldman Sachs & Co. LLC SVB Leerink LLC Evercore Group L.L.C. As representatives (the ?Representatives?) of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o SVB Leerink LLC 1301 Avenue of the Ameri
October 26, 2021	S-1	As filed with the Securities and Exchange Commission on October 26, 2021. Table of Contents As filed with the Securities and Exchange Commission on October 26, 2021.
October 26, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2021 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (C
October 26, 2021	CORRESP	[signature page follows] CORRESP 1 filename1.htm October 26, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Michael Davis Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-260508) Ladies and Gentlemen: Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933,
October 13, 2021	LETTER	LETTER United States securities and exchange commission logo October 13, 2021 David Kirn, M.
October 13, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2021 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation) (C
October 8, 2021	DRS	Confidential Treatment Requested by 4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the Securities and Exchange Commission on October 7, 2021. Table of Contents Confidential Treatment Requested by 4D Molecular Therapeutics, Inc.
September 24, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2021 4D MOLECULAR THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39782 47-3506994 (State or other jurisdiction of incorporation)
September 24, 2021	EX-10.1	Change in Control and Severance Agreement, dated September 22, 2021, by and between David Kirn and 4D Molecular Therapeutics, Inc. Exhibit 10.1 4D MOLECULAR THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the ?Agreement?) is made and entered into by and between David Kirn, M.D. (?Executive?) and 4D Molecular Therapeutics, Inc. (the ?Company?), effective as of the latest date set forth by the signatures of the parties hereto below (the ?Effective Date?). Background A
September 24, 2021	EX-10.2	Change in Control and Severance Agreement, dated September 22, 2021, by and between August Moretti and 4D Molecular Therapeutics, Inc. Exhibit 10.2 4D MOLECULAR THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the ?Agreement?) is made and entered into by and between August Moretti (?Executive?) and 4D Molecular Therapeutics, Inc. (the ?Company?), effective as of the latest date set forth by the signatures of the parties hereto below (the ?Effective Date?). Background A.
September 24, 2021	EX-10.3	Change in Control and Severance Agreement, dated September 22, 2021, by and between Robert Stephen Fishman and 4D Molecular Therapeutics, Inc. Exhibit 10.3 4D MOLECULAR THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the ?Agreement?) is made and entered into by and between Robert Stephen Fishman (?Executive?) and 4D Molecular Therapeutics, Inc. (the ?Company?), effective as of the latest date set forth by the signatures of the parties hereto below (the ?Effective Date?). Backgr
August 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39782 4D Molecula

FDMT / 4D Molecular Therapeutics, Inc. - SEC申報文件，年度報告，委任書

基本數據

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?